Literature DB >> 15252747

[Transient visual decrease after photodynamic therapy].

S Mennel1, N Hausmann, C H Meyer, S Hörle, S Peter.   

Abstract

BACKGROUND: After photodynamic therapy (PDT) some patients complain about a transient decrease of visual acuity during the first postoperative week. PATIENTS AND METHODS: Prior to and at 2 days and 1 week after PDT the following parameters were measured: (1) best corrected visual acuity (VA), (2) changes in refraction, and (3) A scan ultrasound biometry was carried out. Linear and 3-D optical coherence tomography was performed in three cases. A total of 53 PDT treatments were followed-up in 24 patients.
RESULTS: Comparison of the pre- and postoperative refraction demonstrated a mean hyperopic shift of +0.35 diopters (dpt) in 43% of treatments (23/53) on the second postoperative day. The hyperopic shift reduced to +0.07 dpt after 1 week. The best corrected VA remained stable or was even better in 68% (36/53) on the second postoperative day. A decrease in VA could be noticed in 32% (17/53) at this time which declined to 23% (12/53) after 1 week. Measurement of the cornea-retina distance using A-scan ultrasound biometry disclosed a mean axial reduction of 0,13 mm at the second postoperative day. This correlates closely with an average hyperopic shift of 0,35 dpt. OCT examination disclosed a transient macular edema in the treated retinal areas.
CONCLUSIONS: A transient hyperopic shift can be measured in 43% on the second postoperative day. The subjective decrease in visual acuity measured over the postoperative days was mainly due to a transient hyperopic shift in our patients. OCT findings disclosed a transient macular edema of the retina treated with PDT, which may relate to a hyperopic shift.

Entities:  

Mesh:

Year:  2005        PMID: 15252747     DOI: 10.1007/s00347-004-1065-6

Source DB:  PubMed          Journal:  Ophthalmologe        ISSN: 0941-293X            Impact factor:   1.059


  17 in total

Review 1.  [Photodynamic therapy: Recommendations for indication and treatment].

Authors:  U Schmidt-Erfurth; H Laqua
Journal:  Ophthalmologe       Date:  2001-02       Impact factor: 1.059

2.  Immediate indocyanine green angiography and optical coherence tomography evaluation after photodynamic therapy for subfoveal choroidal neovascularization.

Authors:  Rogério A Costa; Michel E Farah; José A Cardillo; Daniela Calucci; George A Williams
Journal:  Retina       Date:  2003-04       Impact factor: 4.256

3.  Optical coherence tomography findings following photodynamic therapy of choroidal neovascularization.

Authors:  Adam H Rogers; Adam Martidis; Paul B Greenberg; Carmen A Puliafito
Journal:  Am J Ophthalmol       Date:  2002-10       Impact factor: 5.258

4.  Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial--VIP report no. 3.

Authors:  Kevin J Blinder; Mark S Blumenkranz; Neil M Bressler; Susan B Bressler; Guy Donato; Hilel Lewis; Jennifer I Lim; Ugo Menchini; Joan W Miller; Jordi M Mones; Michael J Potter; Constantin Pournaras; Al Reaves; Philip Rosenfeld; Andrew P Schachat; Ursula Schmidt-Erfurth; Michel Sickenberg; Lawrence J Singerman; Jason S Slakter; H Andrew Strong; Gianni Virgili; George A Williams
Journal:  Ophthalmology       Date:  2003-04       Impact factor: 12.079

5.  Photodynamic therapy of circumscribed choroidal hemangioma.

Authors:  Giulio Porrini; Alfonso Giovannini; Giampaolo Amato; Alfonso Ioni; Marco Pantanetti
Journal:  Ophthalmology       Date:  2003-04       Impact factor: 12.079

6.  Histological findings of surgically excised choroidal neovascular membranes after photodynamic therapy.

Authors:  U E Schnurrbusch; K Welt; L C Horn; P Wiedemann; S Wolf
Journal:  Br J Ophthalmol       Date:  2001-09       Impact factor: 4.638

7.  Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization--verteporfin in photodynamic therapy report 2.

Authors: 
Journal:  Am J Ophthalmol       Date:  2001-05       Impact factor: 5.258

8.  Sequence of early vascular events after photodynamic therapy.

Authors:  Stephan Michels; Ursula Schmidt-Erfurth
Journal:  Invest Ophthalmol Vis Sci       Date:  2003-05       Impact factor: 4.799

9.  Vascular targeting in photodynamic occlusion of subretinal vessels.

Authors:  U Schmidt-Erfurth; T Hasan; E Gragoudas; N Michaud; T J Flotte; R Birngruber
Journal:  Ophthalmology       Date:  1994-12       Impact factor: 12.079

10.  Liposomal benzoporphyrin derivative verteporfin photodynamic therapy. Selective treatment of choroidal neovascularization in monkeys.

Authors:  M Kramer; J W Miller; N Michaud; R S Moulton; T Hasan; T J Flotte; E S Gragoudas
Journal:  Ophthalmology       Date:  1996-03       Impact factor: 12.079

View more
  4 in total

1.  Optical coherence tomography in photodynamic therapy.

Authors:  S Mennel; F Liu; C H Meyer
Journal:  Br J Ophthalmol       Date:  2005-07       Impact factor: 4.638

2.  Which treatment is best for which AMD patient?

Authors:  P Kroll; C H Meyer
Journal:  Br J Ophthalmol       Date:  2006-02       Impact factor: 4.638

3.  Effect of photodynamic therapy on the function of the outer blood-retinal barrier in an in vitro model.

Authors:  Stefan Mennel; Silvia Peter; Carsten H Meyer; Gabriele Thumann
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-01-19       Impact factor: 3.117

Review 4.  [Monitoring of AMD patients on anti-vascular endothelial growth factor (VEGF) treatment. Practical notes on functional and anatomical examination parameters from drug approval studies, specialist information and case series].

Authors:  C H Meyer; H-M Helb; N Eter
Journal:  Ophthalmologe       Date:  2008-02       Impact factor: 1.059

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.